Background
==========

There are grounds to suspect a connection between Alzheimer\'s disease (AD) and variation in the major histocompatibility complex at the chromosomal region, 6p21.3. AD is characterised by chronic inflammation and altered immune function, including activation of immunocompetent glia expressing high levels of human leukocyte antigen (HLA) molecules, complement and pro-inflammatory cytokines \[[@B1]\]. Many of these proteins are encoded in the region. Genome scans \[[@B2],[@B3]\] have implicated the region. Long-term use of non-steroidal anti-inflammatory drugs is associated with reduced risk of AD \[[@B4]-[@B6]\].

The region has proved a challenge for the study of disease associations, because it is highly variable, with a complex structure of linkage disequilibrium. However, it is also true that, apart from the study of certain genes, e.g. *TNF*\[[@B7]\], and alleles, e.g. HLA-A2 \[[@B8]\], most studies of *HLA*genes in AD have been seriously underpowered. This is particularly so for *HLA-B*and *C*(see Discussion). Our own previous study \[[@B9]\], with 55 cases of AD and 73 controls from the Oxford Project to Investigate Memory and Ageing (OPTIMA), suggested an association with AD of two alleles in linkage disequilibrium with each other, HLA-B7 and *HLA-Cw*\*0702, especially in people without the ε4 allele of apolipoprotein E (*APOE*4). As that association was not replicated in two other cohorts involved in the study \[[@B9]\], it remains possible that these contrasts were due to geographical differences, for instance in the fine structure of linkage disequilibrium or in interactions with other risk factors (see Discussion).

We now examined *HLA-B*and *C*alleles in a further 141 cases of AD and 143 controls from the longitudinal, observational cohort of OPTIMA. Thus, altogether 196 cases of AD and 199 controls were studied, i.e. including 55 cases and 56 controls from our previous study \[[@B9]\] (17 of the 73 controls from that study now have other diagnoses, e.g. mild cognitive impairment, and have therefore been excluded from analysis). We aimed to replicate the association with HLA-B7 and *HLA-Cw*\*0702 and to examine other alleles at those loci.

Methods
=======

All 196 cases of AD (110 women) and 199 controls (107 women) were Caucasians in OPTIMA, drawn from the Oxford region and followed with detailed annual assessments \[[@B10]\] for up to 15 years. The cohorts for both our studies were drawn from the same Oxford population and ascertained in a similar way. OPTIMA protocols \[[@B10]\] have been approved by the Central Oxford Ethics Committee No 1656. Mean onset age of AD was 70.5 (± 8.9) years and of death or last examination of controls was 76.7 (± 9.2) years. Of the AD cases, 122 were neuropathologically confirmed by CERAD criteria \[[@B11]\] (104 \"definite\" and 18 \"probable\") and 74 were diagnosed \"probable AD\" by NINCDS-ADRDA criteria \[[@B12]\]. Possible autosomal dominant cases were excluded, based on family history. All 199 controls were without cognitive impairment and with CAMCOG scores \[[@B13]\] \> 80.

*HLA-B*and *Cw*genotyping was performed by PCR-SSP using a modification of the Phototyping method \[[@B14]\]. Standard PCR methods were used for *APOE*4 \[[@B15]\]. All genotyping was undertaken blind to diagnosis. Unadjusted *p*values were by Fisher\'s exact test; odds ratios were also adjusted for age, gender and *APOE*4 status by logistic regression analysis. Potential interactions were examined by logistic regression analysis. Of the 26 studied alleles, 14 had a minor allele frequency \> 5%. In the overall analyses of each allele, therefore, a Bonferroni correction factor of 14 was applied, except in the replication study of HLA-B7 and *HLA-Cw*\*0702. In subgroup analyses, stratified by gender and by *APOE*4 status, a correction factor of 14 × 4 = 56 was used.

Results
=======

Hardy-Weinberg equilibrium
--------------------------

Out of 52 Hardy-Weinberg analyses (26 analyses of controls and 26 of cases), three resulted in disequilibrium at *p*\< 0.05, as expected by chance: *HLA*-B39 controls, *HLA*-B51 cases and *HLA*-B65 cases, each due to a single homozygote of a relatively rare allele. All other alleles were in Hardy-Weinberg equilibrium in both cases and controls (Tables [1](#T1){ref-type="table"} &[2](#T2){ref-type="table"}).

###### 

*HLA-B*alleles in controls and in Alzheimer\'s disease

  Allele    Homozygotes/heterozygotes/negatives (n)   Allelic frequency (%)   Unadjusted allelic odds ratio of AD (95% CI, *p*^†^)   Hardy-Weinberg equilibrium (*p*^†^)                                   
  --------- ----------------------------------------- ----------------------- ------------------------------------------------------ ------------------------------------- ----------------------- ------- --------
  HLA-B7    0/42/157                                  7/58/131                10.6                                                   18.4                                  1.9 (1.3--2.9, 0.002)   0.1     0.85
  HLA-B8    5/49/145                                  6/45/145                14.8                                                   14.5                                  1.0 (0.7--1.45, 0.9)    0.7     0.3
  HLA-B18   1/16/182                                  1/11/184                4.5                                                    3.3                                   0.7 (0.35--1.5, 0.5)    0.3     0.08
  HLA-B27   0/11/188                                  0/18/178                2.8                                                    4.6                                   1.7 (0.8--3.6, 0.2)     0.7     0.5
  HLA-B35   0/22/177                                  1/25/170                5.5                                                    6.9                                   1.3 (0.7--2.3, 0.5)     0.4     0.9
  HLA-B39   1/9/189                                   0/7/189                 2.8                                                    1.8                                   0.6 (0.25--1.7, 0.5)    0.025   0.8
  HLA-B44   3/56/140                                  7/48/141                15.6                                                   15.8                                  1.0 (0.7--1.5, 1.0)     0.3     0.3
  HLA-B51   0/20/179                                  1/8/187                 5.0                                                    2.6                                   0.5 (0.2--1.1, 0.09)    0.5     0.01
  HLA-B57   0/19/180                                  1/19/176                4.8                                                    5.4                                   1.1 (0.6--2.1, 0.75)    0.5     0.5
  HLA-B60   1/31/167                                  0/19/177                8.3                                                    4.8                                   0.6 (0.3--1.0, 0.06)    0.7     0.5
  HLA-B62   1/31/167                                  0/23/173                8.3                                                    5.9                                   0.7 (0.4--1.2, 0.2)     0.7     0.4
  HLA-B65   0/13/186                                  1/4/191                 3.3                                                    1.5                                   0.5 (0.2--1.2, 0.2)     0.6     0.0001

AD = Alzheimer\'s disease, CI = confidence interval ^†^uncorrected

###### 

*HLA-C*alleles in controls and in Alzheimer\'s disease

  Allele             Homozygotes/heterozygotes/negatives (n)   Allelic frequency (%)   Unadjusted allelic odds ratio of AD (95% CI, *p*^†^)   Hardy-Weinberg equilibrium (*p*^†^)                                    
  ------------------ ----------------------------------------- ----------------------- ------------------------------------------------------ ------------------------------------- ------------------------- ------ ------
  HLA-Cw1            0/9/190                                   1/14/180                2.3                                                    4.1                                   1.85 (0.8--4.2, 0.2)      0.7    0.2
  HLA-Cw2            0/15/184                                  0/16/179                3.8                                                    4.1                                   1.1 (0.5--2.2, 0.9)       0.6    0.55
  HLA-Cw4            1/36/162                                  1/34/160                9.5                                                    9.2                                   1.0 (0.6--1.6, 0.9)       0.5    0.6
  HLA-Cw5            1/36/162                                  1/40/154                9.5                                                    10.8                                  1.1 (0.7--1.8, 0.6)       0.5    0.35
  HLA-Cw6            4/31/164                                  2/31/162                9.8                                                    9.0                                   0.9 (0.6--1.5, 0.7)       0.09   0.7
  *HLA*-*Cw*\*0701   6/62/131                                  7/56/132                18.6                                                   17.9                                  1.0 (0.7--1.4, 0.85)      0.7    0.7
  *HLA*-*Cw*\*0702   1/46/152                                  9/58/128                12.1                                                   19.5                                  1.8 (1.2--2.6, 0.0045)    0.2    0.5
  *HLA*-*Cw*\*0704   0/8/191                                   0/3/192                 2.0                                                    0.8                                   0.4 (0.1--1.4, 0.2)       0.8    0.9
  HLA-Cw8            0/17/182                                  1/11/183                4.3                                                    3.3                                   0.8 (0.4--1.6, 0.6)       0.5    0.08
  HLA-Cw9            0/29/170                                  0/25/170                7.3                                                    6.4                                   0.9 (0.5--1.5, 0.7)       0.3    0.3
  HLA-Cw10           1/37/161                                  2/24/169                9.8                                                    7.2                                   0.7 (0.4--1.2, 0.2)       0.5    0.3
  HLA-Cw12           1/11/187                                  0/8/187                 3.3                                                    2.1                                   0.6 (0.25--1.5, 0.4)      0.08   0.8
  HLA-Cw15           0/13/186                                  0/2/193                 3.3                                                    0.5                                   0.15 (0.03--0.7, 0.007)   0.6    0.9
  HLA-Cw16           0/13/186                                  1/13/181                3.3                                                    3.8                                   1.2 (0.6--2.5, 0.7)       0.6    0.2

AD = Alzheimer\'s disease, CI = confidence interval ^†^uncorrected

Linkage disequilibrium
----------------------

Four well-known examples of linkage disequilibria were confirmed: HLA-B7 and *HLA-Cw*\*0702 (overall D\' = 96%, r^2^= 0.82), HLA-B8 and *HLA-Cw*\*0701 (99%, 0.75), HLA-B35 and Cw4 (96%, 0.58), and HLA-B44 and Cw5 (76%, 0.36). Similar patterns were seen both in controls and in cases.

Possible associations of AD with HLA-B & C alleles
--------------------------------------------------

Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} show the overall results for the 26 studied alleles. Apart from the associations with HLA-B7 and *HLA*-*Cw*\*0702 (see below), there was one other apparently significant association, i.e. with HLA-Cw15, before correction for multiple testing. Subgroup analysis, stratifying by gender and by *APOE*4 status, revealed various other associations before correction: HLA-B27 in *APOE*4 negatives (odds ratio = 2.95, 95% confidence interval = 1.1--7.9, *p*= 0.035); HLA-Cw1 in *APOE*4 negatives (3.4, 1.2--9.6, 0.03) and in men (11.3, 1.4--89, 0.004); HLA-Cw15 in *APOE*4 positives (0.11, 0.01--0.99, 0.03) and in men (0.11, 0.01--0.9, 0.02). There was also a significant interaction between HLA-Cw1 and sex (*p*= 0.03, logistic regression). However, none of these apparently significant results survived Bonferroni correction. Only a weak tendency towards an association with HLA-Cw15 overall remained after correction (*p*= 0.1). All further results reported below relate to HLA-B7 and *HLA*-*Cw*\*0702.

Replication study of HLA-B7 and *HLA-Cw*\*0702
----------------------------------------------

Table [3](#T3){ref-type="table"} shows the results for HLA-B7 and *HLA*-*Cw*\*0702 by study, i.e. our previous study (included in our 2001 report \[[@B9]\]) and the replication study. The association of HLA-B7 with AD was replicated and that of *HLA*-*Cw*\*0702 tended also to be replicated. As expected, similar overall results were found for the HLA-B7/*HLA-Cw*\*0702 haplotype (data not shown). In view of the consistency between the results of the two studies, we pooled the two datasets for further analysis of HLA-B7 and *HLA*-*Cw*\*0702.

###### 

Associations of AD with HLA-B7 and *HLA-Cw*\*0702 by study

  Allele             Study         Proportions of alleles   Adjusted^‡^odds ratios of AD (95% CI, *p*)   
  ------------------ ------------- ------------------------ -------------------------------------------- -----------------------
  HLA-B7             Previous^†^   10/112                   26/110                                       3.1 (1.2--8.0, 0.02)
                     Replication   32/286                   46/282                                       1.9 (1.03--3.4, 0.04)
                     All           42/398                   72/392                                       2.3 (1.4--3.7, 0.001)
                                                                                                         
  *HLA*-*Cw*\*0702   Previous^†^   14/112                   28/108                                       2.7 (1.1--6.3, 0.03)
                     Replication   34/286                   48/282                                       1.7 (0.95--2.9, 0.08)
                     All           48/398                   76/390                                       2.0 (1.3--3.1, 0.003)

^†^results included in our 2001 report \[9\]

AD = Alzheimer\'s disease, CI = confidence interval

^‡^for age, gender and the ε4 allele of apolipoprotein E

Possible interactions of HLA-B7 and *HLA-Cw*\*0702 with other factors
---------------------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the associations of AD with HLA-B7 and *HLA-Cw*\*0702 by *APOE*4 status. Although the odds ratios were higher in *APOE*4 negatives than in positives and were only significant in the former, the differences were not significant. Moreover, neither interaction of HLA-B7 nor of *HLA*-*Cw*\*0702 with *APOE*4 was significant (*p*= 0.27 and 0.55, respectively) by logistic regression analysis. Nor were there any significant interactions with age or gender (data not shown).

###### 

Associations of AD with HLA-B7 and *HLA-Cw*\*0702 by *APOE*4 status

  Allele             *APOE*4 status   Proportions of alleles   Adjusted^†^odds ratios of AD (95% CI, *p*)   
  ------------------ ---------------- ------------------------ -------------------------------------------- -----------------------
  HLA-B7             Positive         14/110                   42/246                                       1.7 (0.8--3.55, 0.19)
                     Negative         28/288                   30/146                                       2.8 (1.5--5.2, 0.002)
                     All              42/398                   72/392                                       2.3 (1.4--3.7, 0.001)
                                                                                                            
  *HLA*-*Cw*\*0702   Positive         14/110                   45/244                                       1.7 (0.8--3.6, 0.15)
                     Negative         34/288                   31/146                                       2.2 (1.2--4.0, 0.01)
                     All              48/398                   76/390                                       2.0 (1.3--3.1, 0.003)

AD = Alzheimer\'s disease, *APOE*4 = the ε4 allele of apolipoprotein E, CI = confidence interval ^†^for age, gender and *APOE*4

Effects of homozygosity of HLA-B7 and *HLA-Cw*\*0702
----------------------------------------------------

Table [5](#T5){ref-type="table"} shows that the odds ratios of AD were much higher for homozygotes than for heterozygotes. In the case of *HLA*-*Cw*\*0702, the odds ratio was only significant for homozygotes.

###### 

Associations of AD with HLA-B7 and *HLA-Cw*\*0702 by zygosity

  Allele             Homozygotes/heterozygotes/negatives(n)   Unadjusted^†^odds ratios of AD (95% CI, *p*) (versus negatives)   
  ------------------ ---------------------------------------- ----------------------------------------------------------------- --------------------------------------
  HLA-B7             0/42/157                                 7/58/131                                                          Heterozygotes: 1.7 (1.02--2.7, 0.04)
                                                                                                                                Homozygotes: 18.0 (1.6--202, 0.0045)
  *HLA*-*Cw*\*0702   1/46/152                                 9/58/128                                                          Heterozygotes: 1.5 (0.9--2.4, 0.09)
                                                                                                                                Homozygotes: 10.7 (1.6--72.0, 0.007)

AD = Alzheimer\'s disease, CI = confidence interval.

^†^Analyses were unadjusted since there were too few homozygotes for regression analysis

The effect on onset age
-----------------------

Neither HLA-B7 nor *HLA*-*Cw*\*0702 was associated with onset age of AD (data not shown).

Discussion
==========

We suggest that the only results meriting further scrutiny are those for HLA-B7 and *HLA-Cw*\*0702 and possibly the potentially reduced risk associated with HLA-Cw15. All other apparently significant results, i.e. before correction, are probably due to multiple testing. However, our replication of the HLA-B7 finding, which was significant in both studies, implies that that allele is indeed associated with increased risk of AD in the Oxford population. The results for *HLA*-*Cw*\*0702 were consistent with those for HLA-B7. Because of the tight linkage disequilibrium between these two alleles and also their similar frequency, we cannot be certain which is closer to the true risk locus.

Previous studies
----------------

To our knowledge, there have been 17 previous AD association studies that included *HLA-B*or *C*alleles or both. Fifteen of those were before 1990, based on phenotyping methods, using AD cases that were nearly all clinically diagnosed, usually by an unspecified method. Two of those early studies \[[@B16],[@B17]\] reported an increased risk of AD associated with HLA-B7. Of the 17 studies, only three had more than 60 AD cases: one Japanese study \[[@B18]\] (122 AD cases) and two Caucasian, Middleton et al 1999 \[[@B19]\] (95 AD cases) and our previous study \[[@B9]\] (299 AD cases from three cohorts; however, full *HLA*-*B*&*C*typing was only performed in the OPTIMA cohort, with 55 AD cases). Thus surprisingly, the present study is the largest, full study of *HLA*-*B*&*C*genes so far, and the only one large enough to examine the effects of homozygosity (Table [5](#T5){ref-type="table"}).

Population-specific risk
------------------------

Since the association with HLA-B7 was not replicated in the two other cohorts in our previous study \[[@B9]\], one mainly from Cambridge and the other from Montreal, the association reported here is likely to be geographically specific, although chance variation doubtless also played a part. This geographical specificity could be due to differences in the fine structure of linkage disequilibrium between populations or to different interactions with other risk factors: environmental, genetic or epigenetic. Epigenetic patterns, such as DNA methylation and chromatin modifications, affect gene expression and are thought to be stably maintained during somatic cell divisions, i.e. they are mitotically heritable. But they vary between tissues and between populations and degenerate with age \[[@B20],[@B21]\]. Most complex diseases are age-related. Thus epigenetic patterns, as well as genetic and environmental factors, will contribute to variation between populations.

Potential interactions
----------------------

In the present study, we found no interactions of HLA-B7 or of *HLA*-*Cw*\*0702 with age, gender or *APOE*4; we consider the apparent difference between *APOE*4 positives and negatives (Table [4](#T4){ref-type="table"}) to be most likely due to chance. This result thus contradicts our previous suggestion \[[@B9]\] of an interaction with *APOE*4. Large numbers, however, are needed to demonstrate interactions.

Homozygosity
------------

The odds ratios for HLA-B7 and *HLA*-*Cw*\*0702 homozygotes appear striking (Table [5](#T5){ref-type="table"}). However, they are partly due to partial (i.e. not significant at 0.05) Hardy-Weinberg disequilibrium in controls (*p*= 0.1 for HLA-B7, *p*= 0.2 for *HLA-Cw*\*0702). Nevertheless, if one were artificially to restore precise Hardy-Weinberg equilibrium to controls, the odds ratios for homozygotes of each allele would still be approximately 4 and those for heterozygotes would remain just below 2. This would still suggest a codominant or dose effect of these alleles. Incidentally, one study \[[@B22]\] reported an association of homozygotes, not of heterozygotes of HLA-A2 with earlier onset of AD; however, HLA-A2 is on a different haplotype from HLA-B7/*HLA*-*Cw*\*0702/HLA-A3.

Alternatively, could the lack of homozygotes in controls (Table [5](#T5){ref-type="table"}) be a true effect due to their selective vulnerability, not only to AD? Low natural killer (NK) cell activity has been associated with homozygosity for both the HLA-B7/*HLA*-*Cw*\*0702 and the HLA-B8/*HLA*-*Cw*\*0701 haplotypes in Caucasians \[[@B23],[@B24]\] and for HLA-B7 in Chinese \[[@B25]\]. This low NK cell activity may be due to a recessive gene or variable site in linkage disequilibrium with these haplotypes. In our previous study \[[@B9]\], AD was associated with HLA-B7 in one cohort and with HLA-B8 in another, mainly or only in subjects without *APOE*4.

Homozygosity at *HLA*class I loci has been associated with greater susceptibility to viral infection \[[@B26],[@B27]\], perhaps partly due to an inadequate defence by NK cells \[[@B24]\]. However, this effect was not seen in our cohort, since there was no overall shortage of homozygotes, only in controls. Alternatively therefore, could it be that low NK cell activity increases vulnerability to AD?

NK cells and AD
---------------

NK activity has been rather little studied in AD. However, there may be changes in the peripheral activity of NK cells in AD, although reports conflict \[[@B28]-[@B31]\]. It has been proposed that the dysregulation of NK activity and of cytokine release by NK cells in AD could contribute to neurodegeneration, via disrupted release of cortisol, growth hormone, insulin-like growth factors and melatonin \[[@B30]\]. However, the effect if any of lifelong, reduced NK activity on AD risk is unknown.

Conclusion
==========

The HLA-B7 &*HLA*-*Cw*\*0702 alleles, which are in tight linkage disequilibrium, are associated with AD in the Oxford population. Homozygotes may be at particular risk. Although surprisingly, this is the largest study to date of the association of *HLA-B*&*C*alleles with AD, a much larger, probably collaborative study will be needed fully to examine the association with homozygosity. If that association is confirmed, further studies will be needed to provide an explanation, including the possible role of low NK cell activity. The association is geographically specific. That may be partly due to differences in linkage disequilibrium with other genes or variable sites. There are many, highly polymorphic loci in the region, including those in retroelements, some of which may interfere with the transcription of nearby genes \[[@B32]\]. The geographical specificity may also be due to different interactions in different populations with environmental, genetic or epigenetic factors.
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